The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: A randomized, placebo-controlled, double-blind, crossover study

David Allen, Barbara McDonnell, Neil Wheeler, Raj K. Sharma, Andrew Sykes, Ashley Woodcock

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Objective: This study examined the clinical relevance of fine-particle mass (FPM) delivered from metered dose inhalers (MDIs) to bronchodilatation and bronchoprotection against methacholine challenge by comparing a marketed chlorofluorocarbon (CFC) formulation of salmeterol with an investigational hydrofluoroalkane (HFA) formulation. Methods: This was a randomized, double-blind, placebo-controlled, 3-way crossover study in patients with mild to moderate asthma who had a forced expiratory volume in 1 second (FEV 1) of
    Original languageEnglish
    Pages (from-to)1004-1012
    Number of pages8
    JournalClinical Therapeutics
    Volume27
    Issue number7
    DOIs
    Publication statusPublished - Jul 2005

    Keywords

    • Asthma
    • Chlorofluorocarbon
    • Fine-particle mass
    • Hydrofluoroalkane
    • Methacholine challenge
    • Salmeterol

    Fingerprint

    Dive into the research topics of 'The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: A randomized, placebo-controlled, double-blind, crossover study'. Together they form a unique fingerprint.

    Cite this